Lantheus wins final FDA approval for BRAVNETSA radiopharmaceutical in GEP-NETs

By Public Technologies
  • Lantheus won final FDA clearance for BRAVNETSA (lutetium Lu 177 dotatate) to treat adult somatostatin receptor-positive GEP-NETs.
  • FDA deemed BRAVNETSA bioequivalent, therapeutically equivalent to Novartis’ LUTATHERA, enabling substitution under the ANDA pathway.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220800PRIMZONEFULLFEED9831173) on September 22, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk